Showing 1 - 9 results of 9 for search 'Bryan T. Hennessy', query time: 0.02s
Refine Results
-
1
Case report: Clonal evolution analysis of a rare case of meningioma lung metastases identifies actionable alterations in matched longitudinal tumour samples by Nicola Cosgrove, Orla M. Fitzpatrick, Orla M. Fitzpatrick, Liam Grogan, Liam Grogan, Bryan T. Hennessy, Bryan T. Hennessy, Simon J. Furney, Sinead Toomey
Published 2025-01-01Get full text
Article -
2
Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma by Jack Patrick Gleeson, Fergus Keane, Niamh M. Keegan, Emin Mammadov, Emily Harrold, Abdullah Alhusaini, Jeffrey Harte, Austin Eakin‐Love, Philip J. O'Halloran, Stephen MacNally, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris
Published 2020-01-01Get full text
Article -
3
Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer by Aoife Carr, Jonathan A. Coulter, Julie Workman, Joanna Fay, Angela Farrelly, Alex J. Eustace, Lindsey Bennie, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Deborah A. McNamara, Mattia Cremona, Brian D.P. O'Neill, Bryan T. Hennessy, Sinead Toomey
Published 2025-01-01Get full text
Article -
4
Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: a retrospective institutional review of clinical outcomes and hematological toxicity by Ronan Andrew McLaughlin, David McMahon, Christopher Cluxton, Orla Meave Fitzpatrick, Michael Conroy, Majid Almeraikhi, Humaid Alkaabi, Fianait Bligh, Brian O’Neill, Mayilone Arumugasamy, William Robb, Oscar Seamus Breathnach, William Grogan, Bryan T. Hennessy, Adrian Murphy, Jarsuhka Naidoo, Megan Greally, Kathleen Bennett, Patrick G Morris
Published 2025-08-01Get full text
Article -
5
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities by Eunice S. Li, Rebecca Ho, Ran Tao, Yannes Wai Yan Choi, Chae Young Shin, Shary Y. Chen, Bengul Gokbayrak, Janine Senz, Betty Yao, Liam Johnston, Spencer D. Martin, Eric Yang, Mark S. Carey, Bryan T. Hennessy, David G. Huntsman, Ramon I. Klein Geltink, Lynn Hoang, Yemin Wang
Published 2025-07-01Get full text
Article -
6
Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer by Gavin P. Dowling, Aisling Hegarty, Gordon R. Daly, Sandra Hembrecht, Cian M. Hehir, Gavin G. Calpin, Richard Hogan, David O’Reilly, Eithne Downey, Sinead Toomey, Liam Grogan, Oscar Breathnach, Michael Allen, Patrick G. Morris, Colm Power, Leonie S. Young, Arnold D. K. Hill, Bryan T. Hennessy
Published 2025-05-01Get full text
Article -
7
TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast can... by John Crown, Alex J. Eustace, Denis M. Collins, Maccon Keane, Linda Coate, John Kennedy, Seamus O'Reilly, Catherine Kelly, Miriam O'Connor, Michael Martin, Conleth Murphy, Karen Duffy, Janice Walshe, Giuseppe Gullo, Thamir Mahgoub, Alberto Alvarez-Iglesias, Imelda Parker, Vicky Donachie, Ausra Teiserskiene, Stephen F. Madden, Brian Moulton, Norma O'Donovan, Bryan T. Hennessy
Published 2025-06-01Get full text
Article -
8
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers by Peter Gallagher, Christian Rolfo, Elena Elez, Julien Taieb, Jennifer Houlden, Linda Collins, Corran Roberts, Thierry André, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Vlad Popovici, Alberto Bardelli, Robbie Carson, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Bryan T. Hennessy, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium
Published 2025-03-01Get full text
Article -
9
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) by Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium
Published 2025-04-01Get full text
Article